10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CYCN (Cyclerion) Stock Analysis
Buy, Hold or Sell?

Let's analyze Cyclerion together

I guess you are interested in Cyclerion Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Cyclerion’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Cyclerion’s Price Targets

I'm going to help you getting a better view of Cyclerion Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Cyclerion Therapeutics Inc

I send you an email if I find something interesting about Cyclerion Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Cyclerion (30 sec.)










1.2. What can you expect buying and holding a share of Cyclerion? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.87
Expected worth in 1 year
$2.49
How sure are you?
38.7%

+ What do you gain per year?

Total Gains per Share
$-0.37
Return On Investment
-11.1%

For what price can you sell your share?

Current Price per Share
$3.36
Expected price per share
$2.7 - $9.4699
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Cyclerion (5 min.)




Live pricePrice per Share (EOD)
$3.36
Intrinsic Value Per Share
$-29.68 - $-34.08
Total Value Per Share
$-26.81 - $-31.21

2.2. Growth of Cyclerion (5 min.)




Is Cyclerion growing?

Current yearPrevious yearGrowGrow %
How rich?$8.7m$9.8m-$1.1m-13.4%

How much money is Cyclerion making?

Current yearPrevious yearGrowGrow %
Making money-$736k$37.2k-$773.2k-105.1%
Net Profit Margin-526.9%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Cyclerion (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#605 / 881

Most Revenue
#497 / 881

Most Profit
#225 / 881

Most Efficient
#666 / 881
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Cyclerion?

Welcome investor! Cyclerion's management wants to use your money to grow the business. In return you get a share of Cyclerion.

First you should know what it really means to hold a share of Cyclerion. And how you can make/lose money.

Speculation

The Price per Share of Cyclerion is $3.36. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cyclerion.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cyclerion, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.87. Based on the TTM, the Book Value Change Per Share is $-0.09 per quarter. Based on the YOY, the Book Value Change Per Share is $0.49 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cyclerion.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.47-13.9%-0.24-7.2%0.010.4%-0.51-15.1%-1.66-49.3%-3.57-106.4%
Usd Book Value Change Per Share-0.02-0.7%-0.09-2.8%0.4914.6%0.175.0%-1.19-35.4%0.092.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.02-0.7%-0.09-2.8%0.4914.6%0.175.0%-1.19-35.4%0.092.8%
Usd Price Per Share2.50-2.65-3.52-2.27-2.74-3.38-
Price to Earnings Ratio-1.34--0.19--0.88--0.48--0.53--0.40-
Price-to-Total Gains Ratio-109.32--28.48--0.50--10.18--6.30--5.49-
Price to Book Ratio0.87-0.94-1.29-1.05-0.91-0.36-
Price-to-Total Gains Ratio-109.32--28.48--0.50--10.18--6.30--5.49-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.36
Number of shares297
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.09-1.19
Usd Total Gains Per Share-0.09-1.19
Gains per Quarter (297 shares)-27.73-352.99
Gains per Year (297 shares)-110.90-1,411.97
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-111-1210-1412-1422
20-222-2320-2824-2834
30-333-3430-4236-4246
40-444-4540-5648-5658
50-555-5650-7060-7070
60-665-6760-8472-8482
70-776-7870-9884-9894
80-887-8980-11296-11306
90-998-10090-12708-12718
100-1109-11200-14120-14130

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%2.018.00.010.0%2.028.01.06.5%2.028.01.06.5%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%12.019.00.038.7%12.019.00.038.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.031.00.0%0.00.031.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%12.019.00.038.7%12.019.00.038.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Cyclerion Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.023-0.093+308%0.490-105%0.168-114%-1.189+5097%0.093-125%
Book Value Per Share--2.8682.827+1%3.204-10%2.482+16%6.769-58%7.637-62%
Current Ratio--4.2154.697-10%3.418+23%3.439+23%3.910+8%3.326+27%
Debt To Asset Ratio--0.1080.098+11%0.232-53%0.251-57%0.281-61%0.777-86%
Debt To Equity Ratio--0.1220.109+12%0.368-67%0.455-73%0.500-76%0.421-71%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--10224350.00010758393.350-5%15082411.150-32%17140827.325-40%33620070.145-70%38510459.916-73%
Eps---0.467-0.240-48%0.012-3936%-0.508+9%-1.656+255%-3.574+666%
Ev To Ebitda Ratio---1.7540.074-2476%-1.744-1%-0.747-57%-0.876-50%-0.802-54%
Ev To Sales Ratio--31.55715.428+105%--40.274-22%65.531-52%52.571-40%
Free Cash Flow Per Share---0.316-0.280-11%-1.380+337%-0.954+202%-1.554+391%-3.309+946%
Free Cash Flow To Equity Per Share--0.133-0.168+226%-0.970+830%-0.780+686%-0.491+470%0.693-81%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%0.968+3%
Intrinsic Value_10Y_max---34.082----------
Intrinsic Value_10Y_min---29.679----------
Intrinsic Value_1Y_max---3.764----------
Intrinsic Value_1Y_min---3.697----------
Intrinsic Value_3Y_max---11.043----------
Intrinsic Value_3Y_min---10.548----------
Intrinsic Value_5Y_max---18.002----------
Intrinsic Value_5Y_min---16.732----------
Market Cap10284758.400+26%7652350.0008119143.350-6%10782161.150-29%11682660.658-34%21382170.145-64%20888145.093-63%
Net Profit Margin---17.642-5.269-70%--100%-17.5600%-45.670+159%-31.945+81%
Operating Margin----0%-0%-15.9300%-45.4870%-31.9370%
Operating Ratio--18.9886.631+186%-+100%18.238+4%47.783-60%33.560-43%
Pb Ratio1.171+26%0.8720.938-7%1.289-32%1.054-17%0.909-4%0.365+139%
Pe Ratio-1.799-34%-1.339-0.191-86%-0.877-34%-0.477-64%-0.534-60%-0.405-70%
Price Per Share3.360+26%2.5002.653-6%3.523-29%2.267+10%2.742-9%3.381-26%
Price To Free Cash Flow Ratio-2.656-34%-1.9760.530-473%-0.958-52%-0.277-86%-0.489-75%-0.382-81%
Price To Total Gains Ratio-146.925-34%-109.319-28.482-74%-0.499-100%-10.181-91%-6.298-94%-5.486-95%
Quick Ratio--3.9554.231-7%3.153+25%3.149+26%3.666+8%3.138+26%
Return On Assets---0.145-0.076-48%-0.045-69%-0.188+29%-0.184+27%-312.378+215155%
Return On Equity---0.163-0.085-48%-0.132-19%-0.368+126%-0.329+102%-0.244+50%
Total Gains Per Share---0.023-0.093+308%0.490-105%0.168-114%-1.189+5097%0.093-125%
Usd Book Value--8780000.0008652750.000+1%9808500.000-10%10842250.000-19%29318850.000-70%31431105.701-72%
Usd Book Value Change Per Share---0.023-0.093+308%0.490-105%0.168-114%-1.189+5097%0.093-125%
Usd Book Value Per Share--2.8682.827+1%3.204-10%2.482+16%6.769-58%7.637-62%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--10224350.00010758393.350-5%15082411.150-32%17140827.325-40%33620070.145-70%38510459.916-73%
Usd Eps---0.467-0.240-48%0.012-3936%-0.508+9%-1.656+255%-3.574+666%
Usd Free Cash Flow---968000.000-857500.000-11%-4225500.000+337%-4526833.333+368%-7355850.000+660%-12507935.484+1192%
Usd Free Cash Flow Per Share---0.316-0.280-11%-1.380+337%-0.954+202%-1.554+391%-3.309+946%
Usd Free Cash Flow To Equity Per Share--0.133-0.168+226%-0.970+830%-0.780+686%-0.491+470%0.693-81%
Usd Market Cap10284758.400+26%7652350.0008119143.350-6%10782161.150-29%11682660.658-34%21382170.145-64%20888145.093-63%
Usd Price Per Share3.360+26%2.5002.653-6%3.523-29%2.267+10%2.742-9%3.381-26%
Usd Profit---1429000.000-736000.000-48%37250.000-3936%-3351916.667+135%-8120750.000+468%-14469612.903+913%
Usd Revenue--81000.000520250.000-84%-+100%314833.333-74%430300.000-81%455709.677-82%
Usd Total Gains Per Share---0.023-0.093+308%0.490-105%0.168-114%-1.189+5097%0.093-125%
 EOD+5 -3MRQTTM+14 -22YOY+14 -213Y+20 -165Y+24 -1210Y+18 -19

3.3 Fundamental Score

Let's check the fundamental score of Cyclerion Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.799
Price to Book Ratio (EOD)Between0-11.171
Net Profit Margin (MRQ)Greater than0-17.642
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.955
Current Ratio (MRQ)Greater than14.215
Debt to Asset Ratio (MRQ)Less than10.108
Debt to Equity Ratio (MRQ)Less than10.122
Return on Equity (MRQ)Greater than0.15-0.163
Return on Assets (MRQ)Greater than0.05-0.145
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Cyclerion Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.165
Ma 20Greater thanMa 503.074
Ma 50Greater thanMa 1003.107
Ma 100Greater thanMa 2002.911
OpenGreater thanClose3.350
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Cyclerion Therapeutics Inc

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2025-06-19 03:46:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Cyclerion earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Cyclerion to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -1,764.2%Β means thatΒ $-17.64 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cyclerion Therapeutics Inc:

  • The MRQ is -1,764.2%. The company is making a huge loss. -2
  • The TTM is -526.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,764.2%TTM-526.9%-1,237.3%
TTM-526.9%YOY--526.9%
TTM-526.9%5Y-4,567.0%+4,040.1%
5Y-4,567.0%10Y-3,194.5%-1,372.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,764.2%-91.7%-1,672.5%
TTM-526.9%-139.0%-387.9%
YOY--194.4%+194.4%
3Y-1,756.0%-248.5%-1,507.5%
5Y-4,567.0%-343.3%-4,223.7%
10Y-3,194.5%-488.9%-2,705.6%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Cyclerion is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Cyclerion to theΒ Biotechnology industry mean.
  • -14.5% Return on Assets means thatΒ Cyclerion generatedΒ $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cyclerion Therapeutics Inc:

  • The MRQ is -14.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.5%TTM-7.6%-7.0%
TTM-7.6%YOY-4.5%-3.1%
TTM-7.6%5Y-18.4%+10.9%
5Y-18.4%10Y-31,237.8%+31,219.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.5%-11.6%-2.9%
TTM-7.6%-11.7%+4.1%
YOY-4.5%-11.4%+6.9%
3Y-18.8%-11.9%-6.9%
5Y-18.4%-12.1%-6.3%
10Y-31,237.8%-13.8%-31,224.0%
4.3.1.3. Return on Equity

Shows how efficient Cyclerion is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Cyclerion to theΒ Biotechnology industry mean.
  • -16.3% Return on Equity means Cyclerion generated $-0.16Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cyclerion Therapeutics Inc:

  • The MRQ is -16.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -8.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.3%TTM-8.5%-7.7%
TTM-8.5%YOY-13.2%+4.7%
TTM-8.5%5Y-32.9%+24.4%
5Y-32.9%10Y-24.4%-8.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.3%-13.5%-2.8%
TTM-8.5%-15.0%+6.5%
YOY-13.2%-14.5%+1.3%
3Y-36.8%-16.9%-19.9%
5Y-32.9%-17.9%-15.0%
10Y-24.4%-19.9%-4.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Cyclerion Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Cyclerion is operatingΒ .

  • Measures how much profit Cyclerion makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Cyclerion to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cyclerion Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-4,548.7%+4,548.7%
5Y-4,548.7%10Y-3,193.7%-1,354.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM--249.7%+249.7%
YOY--208.4%+208.4%
3Y-1,593.0%-221.7%-1,371.3%
5Y-4,548.7%-344.1%-4,204.6%
10Y-3,193.7%-470.4%-2,723.3%
4.3.2.2. Operating Ratio

Measures how efficient Cyclerion is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 18.99 means that the operating costs are $18.99 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cyclerion Therapeutics Inc:

  • The MRQ is 18.988. The company is inefficient in keeping operating costs low. -1
  • The TTM is 6.631. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ18.988TTM6.631+12.357
TTM6.631YOY-+6.631
TTM6.6315Y47.783-41.152
5Y47.78310Y33.560+14.224
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ18.9882.108+16.880
TTM6.6312.680+3.951
YOY-3.080-3.080
3Y18.2383.621+14.617
5Y47.7834.734+43.049
10Y33.5606.546+27.014
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Cyclerion Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Cyclerion is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 4.21Β means the company has $4.21 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cyclerion Therapeutics Inc:

  • The MRQ is 4.215. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.697. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.215TTM4.697-0.483
TTM4.697YOY3.418+1.279
TTM4.6975Y3.910+0.787
5Y3.91010Y3.326+0.584
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.2153.659+0.556
TTM4.6973.834+0.863
YOY3.4184.141-0.723
3Y3.4394.661-1.222
5Y3.9105.756-1.846
10Y3.3266.151-2.825
4.4.3.2. Quick Ratio

Measures if Cyclerion is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Cyclerion to theΒ Biotechnology industry mean.
  • A Quick Ratio of 3.96Β means the company can pay off $3.96 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cyclerion Therapeutics Inc:

  • The MRQ is 3.955. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.231. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.955TTM4.231-0.276
TTM4.231YOY3.153+1.078
TTM4.2315Y3.666+0.565
5Y3.66610Y3.138+0.528
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9552.799+1.156
TTM4.2313.143+1.088
YOY3.1533.794-0.641
3Y3.1494.307-1.158
5Y3.6665.707-2.041
10Y3.1386.457-3.319
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Cyclerion Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of CyclerionΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Cyclerion to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.11Β means that Cyclerion assets areΒ financed with 10.8% credit (debt) and the remaining percentage (100% - 10.8%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Cyclerion Therapeutics Inc:

  • The MRQ is 0.108. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.098. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.108TTM0.098+0.011
TTM0.098YOY0.232-0.134
TTM0.0985Y0.281-0.184
5Y0.28110Y0.777-0.495
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1080.324-0.216
TTM0.0980.347-0.249
YOY0.2320.329-0.097
3Y0.2510.340-0.089
5Y0.2810.349-0.068
10Y0.7770.379+0.398
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Cyclerion is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Cyclerion to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 12.2% means that company has $0.12 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cyclerion Therapeutics Inc:

  • The MRQ is 0.122. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.109. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.122TTM0.109+0.013
TTM0.109YOY0.368-0.259
TTM0.1095Y0.500-0.391
5Y0.50010Y0.421+0.079
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1220.379-0.257
TTM0.1090.435-0.326
YOY0.3680.412-0.044
3Y0.4550.446+0.009
5Y0.5000.460+0.040
10Y0.4210.509-0.088
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Cyclerion generates.

  • Above 15 is considered overpriced butΒ always compareΒ Cyclerion to theΒ Biotechnology industry mean.
  • A PE ratio of -1.34 means the investor is paying $-1.34Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cyclerion Therapeutics Inc:

  • The EOD is -1.799. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.339. Based on the earnings, the company is expensive. -2
  • The TTM is -0.191. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.799MRQ-1.339-0.461
MRQ-1.339TTM-0.191-1.148
TTM-0.191YOY-0.877+0.687
TTM-0.1915Y-0.534+0.344
5Y-0.53410Y-0.405-0.130
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.799-2.282+0.483
MRQ-1.339-2.062+0.723
TTM-0.191-2.541+2.350
YOY-0.877-3.722+2.845
3Y-0.477-3.754+3.277
5Y-0.534-6.100+5.566
10Y-0.405-6.653+6.248
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cyclerion Therapeutics Inc:

  • The EOD is -2.656. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.976. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 0.530. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-2.656MRQ-1.976-0.680
MRQ-1.976TTM0.530-2.507
TTM0.530YOY-0.958+1.488
TTM0.5305Y-0.489+1.019
5Y-0.48910Y-0.382-0.107
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.656-3.101+0.445
MRQ-1.976-2.689+0.713
TTM0.530-3.594+4.124
YOY-0.958-4.363+3.405
3Y-0.277-5.065+4.788
5Y-0.489-8.478+7.989
10Y-0.382-9.273+8.891
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Cyclerion is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.87 means the investor is paying $0.87Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cyclerion Therapeutics Inc:

  • The EOD is 1.171. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.872. Based on the equity, the company is cheap. +2
  • The TTM is 0.938. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.171MRQ0.872+0.300
MRQ0.872TTM0.938-0.067
TTM0.938YOY1.289-0.351
TTM0.9385Y0.909+0.029
5Y0.90910Y0.365+0.544
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.1711.932-0.761
MRQ0.8721.848-0.976
TTM0.9382.119-1.181
YOY1.2892.469-1.180
3Y1.0542.526-1.472
5Y0.9093.667-2.758
10Y0.3654.351-3.986
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cyclerion Therapeutics Inc.

4.8.1. Institutions holding Cyclerion Therapeutics Inc

Institutions are holding 12.218% of the shares of Cyclerion Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Tyndall Management, LLC5.383210016477700
2025-03-31TYNDALL CAPITAL PARTNERS L P5.383210016477700
2025-03-31Siren, L.L.C.3.79470.016411615500
2025-03-31Geode Capital Management, LLC1.0325031603-217-0.682
2025-03-31Vanguard Group Inc0.767402349000
2025-03-31BlackRock Inc0.548801679700
2024-12-31UBS Group AG0.31580966795226566.8966
2025-03-31FMR Inc0.1614049402004.2194
2025-03-31Tower Research Capital LLC0.03440.00011054-1387-56.821
2025-03-31Morgan Stanley - Brokerage Accounts0.0212064900
2025-03-31Group One Trading, LP0.0176054000
2025-03-31Advisor Group Holdings, Inc.0.0042013000
2025-03-31Mccormack Advisors International0.0033010000
2025-03-31Activest Wealth Management0.00330.000110000
2025-03-31ZRC WEALTH MANAGEMENT, LLC0.000702000
2025-03-31Bank of America Corp0.000601900
2025-03-31SBI Securities Co Ltd0.000401100
2025-03-31BNP Paribas Arbitrage, SA0.00020500
2025-03-31Northwestern Mutual Wealth Management Co00100
2024-12-31MFN Partners Management, LP000-169460-100
Total 17.4729200.0166534835-161342-30.2%

4.9.2. Funds holding Cyclerion Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr0.76740.00012349000
2025-04-30LUX IM Global Medtech HX0.53670.03491642800
2025-05-30Fidelity Nasdaq Composite ETF0.42940.00051314500
2025-04-30Fidelity Extended Market Index0.36520.000111179-106-0.9393
2025-03-31Extended Equity Market Fund K0.09690.0001296690.3044
2025-04-30Fidelity Series Total Market Index0.08730267100
2025-04-30Dimensional US Core Equity USD Acc0.07770.0028237900
2025-04-30Fidelity Total Market Index0.07380226000
2025-03-31NT Ext Equity Mkt Idx Fd - L0.05630.0001172200
2025-03-31Northern Trust Extended Eq Market Idx0.05630.0001172200
2025-04-30Spartan Extended Market Index Pool F0.05560.000117011066.6458
2025-03-31NT Ext Equity Mkt Idx Fd - NL0.05510.0001168600
2025-03-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.04290.00011312-24-1.7964
2025-04-30Spartan Total Market Index Pool G0.03370103126835.1245
2025-05-31State St US Extended Mkt Indx NL Cl C0.01640.000150300
2025-03-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.01350.000141430.7299
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.01340.00014104100
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T40.01340.00014104100
2025-03-31Extended Equity Market Fund M0.01210.0001371-13-3.3854
2025-03-31BNYM Mellon SL Market Completion UC10.01010.0002309-1-0.3226
Total 2.81320.039786109+1062+1.2%

5.3. Insider Transactions

Insiders are holding 32.728% of the shares of Cyclerion Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-08-09Terrance McguireSELL83.4
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets9,847
Total Liabilities1,067
Total Stockholder Equity8,780
 As reported
Total Liabilities 1,067
Total Stockholder Equity+ 8,780
Total Assets = 9,847

Assets

Total Assets9,847
Total Current Assets4,497
Long-term Assets5,350
Total Current Assets
Cash And Cash Equivalents 3,639
Net Receivables 581
Other Current Assets 277
Total Current Assets  (as reported)4,497
Total Current Assets  (calculated)4,497
+/-0
Long-term Assets
Long Term Investments 5,350
Long-term Assets  (as reported)5,350
Long-term Assets  (calculated)5,350
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,067
Long-term Liabilities0
Total Stockholder Equity8,780
Total Current Liabilities
Accounts payable 483
Other Current Liabilities 101
Total Current Liabilities  (as reported)1,067
Total Current Liabilities  (calculated)584
+/- 483
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Retained Earnings -268,921
Other Stockholders Equity 277,701
Total Stockholder Equity (as reported)8,780
Total Stockholder Equity (calculated)8,780
+/-0
Other
Cash and Short Term Investments 3,639
Common Stock Shares Outstanding 2,556
Liabilities and Stockholders Equity 9,847
Net Debt -3,639
Net Invested Capital 8,780
Net Working Capital 3,430



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302016-12-31
> Total Assets 
3,875
0
5,470
3
6,662
6,756
7,401
9,773
235,503
209,704
186,478
140,030
128,038
131,402
115,378
99,967
75,732
67,742
59,331
46,525
35,213
25,053
18,079
11,456
10,097
15,214
13,374
11,364
10,065
8,898
9,575
9,847
9,8479,5758,89810,06511,36413,37415,21410,09711,45618,07925,05335,21346,52559,33167,74275,73299,967115,378131,402128,038140,030186,478209,704235,5039,7737,4016,7566,66235,47003,875
   > Total Current Assets 
0
0
0
0
1,259
862
879
939
144,693
120,706
101,197
70,126
59,562
70,124
58,501
44,446
72,989
63,682
55,457
42,836
31,679
21,656
14,820
8,335
7,113
9,864
8,024
6,014
4,715
3,548
4,225
4,497
4,4974,2253,5484,7156,0148,0249,8647,1138,33514,82021,65631,67942,83655,45763,68272,98944,44658,50170,12459,56270,126101,197120,706144,6939398798621,2590000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
141,030
117,034
94,895
67,096
56,462
66,840
54,395
41,429
70,390
62,503
53,961
41,125
30,323
20,405
13,382
7,169
5,641
9,108
7,571
5,696
4,588
2,872
3,232
3,639
3,6393,2322,8724,5885,6967,5719,1085,6417,16913,38220,40530,32341,12553,96162,50370,39041,42954,39566,84056,46267,09694,895117,034141,03000000000
       Net Receivables 
0
0
0
0
0
0
0
0
1,857
1,440
1,474
1,026
751
400
127
0
0
158
100
227
227
227
96
96
0
0
0
0
0
44
556
581
58155644000009696227227227100158001274007511,0261,4741,4401,85700000000
       Inventory 
0
0
0
0
0
0
0
0
1,778
2,164
1,966
1,868
2,260
1,218
816
0
0
562
928
1,007
647
536
805
567
0
0
0
0
0
0
0
0
000000005678055366471,007928562008161,2182,2601,8681,9662,1641,77800000000
   > Long-term Assets 
0
0
0
0
0
0
6,522
8,834
90,810
88,998
85,281
69,904
68,476
61,278
56,877
55,521
2,743
4,060
3,874
3,689
3,534
3,397
3,259
3,121
2,984
5,350
5,350
5,350
5,350
5,350
5,350
5,350
5,3505,3505,3505,3505,3505,3505,3502,9843,1213,2593,3973,5343,6893,8744,0602,74355,52156,87761,27868,47669,90485,28188,99890,8108,8346,522000000
       Property Plant Equipment 
3,600
0
4,131
2
5,346
5,858
6,497
8,815
83,084
81,272
79,750
63,854
62,093
54,576
50,267
49,003
153
1,561
1,467
1,373
1,310
1,264
1,218
1,171
1,125
0
126
126
0
0
126
0
01260012612601,1251,1711,2181,2641,3101,3731,4671,56115349,00350,26754,57662,09363,85479,75081,27283,0848,8156,4975,8585,34624,13103,600
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,350
5,350
5,350
5,350
5,350
5,350
5,350
5,3505,3505,3505,3505,3505,3505,3500000000000000000000000000
       Other Assets 
0
0
80
0
57
36
25
19
7,726
7,726
5,531
6,050
6,383
6,702
50,012
6,518
2,590
2,499
2,407
2,316
2,224
2,133
2,041
0
0
0
0
0
0
0
0
0
0000000002,0412,1332,2242,3162,4072,4992,5906,51850,0126,7026,3836,0505,5317,7267,7261925365708000
> Total Liabilities 
10,636
0
14,037
7
16,682
14,876
17,846
17,525
94,313
90,507
88,749
58,490
61,937
56,048
55,885
51,534
10,510
11,355
11,085
9,491
9,852
8,529
7,627
7,531
4,947
2,341
2,086
1,441
1,282
700
725
1,067
1,0677257001,2821,4412,0862,3414,9477,5317,6278,5299,8529,49111,08511,35510,51051,53455,88556,04861,93758,49088,74990,50794,31317,52517,84614,87616,682714,037010,636
   > Total Current Liabilities 
10,636
0
14,037
7
16,682
14,876
17,846
17,473
21,916
19,096
18,249
11,435
15,645
16,262
16,952
13,467
10,510
11,355
11,085
9,491
9,852
8,529
7,627
7,531
4,947
2,341
2,086
1,441
1,282
700
725
1,067
1,0677257001,2821,4412,0862,3414,9477,5317,6278,5299,8529,49111,08511,35510,51013,46716,95216,26215,64511,43518,24919,09621,91617,47317,84614,87616,682714,037010,636
       Short-term Debt 
0
0
0
0
0
0
0
0
1,732
6,500
3,420
5,336
6,296
6,642
6,802
6,894
3,509
3,509
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000003,5093,5096,8946,8026,6426,2965,3363,4206,5001,73200000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
3,509
3,509
3,509
3,509
3,509
3,509
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000003,5093,5093,5093,5093,5093,509000000000000
       Accounts payable 
1,410
0
1,802
1
3,655
2,943
2,781
5,671
8,783
5,005
3,311
1,522
2,588
1,855
1,435
1,095
1,386
1,174
1,828
2,519
2,767
1,645
2,970
3,925
1,864
814
1,198
741
651
304
390
483
4833903046517411,1988141,8643,9252,9701,6452,7672,5191,8281,1741,3861,0951,4351,8552,5881,5223,3115,0058,7835,6712,7812,9433,65511,80201,410
       Other Current Liabilities 
9,226
0
12,235
1
1,337
5
15,065
11,802
11,401
7,591
11,518
4,577
6,761
7,765
8,715
5,478
5,615
6,672
9,257
6,972
7,085
6,884
4,657
3,606
3,083
1,527
888
700
631
396
335
101
1013353966317008881,5273,0833,6064,6576,8847,0856,9729,2576,6725,6155,4788,7157,7656,7614,57711,5187,59111,40111,80215,06551,337112,23509,226
   > Long-term Liabilities 
0
0
0
0
0
0
0
52
72,397
71,411
70,500
47,055
46,292
39,786
38,933
38,067
0
0
1,828
2,519
2,767
1,645
2,970
3,925
0
0
0
0
0
0
0
0
000000003,9252,9701,6452,7672,5191,8280038,06738,93339,78646,29247,05570,50071,41172,397520000000
       Other Liabilities 
0
0
0
0
0
0
0
52
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000520000000
> Total Stockholder Equity
0
0
0
-8,567
-10,020
-8,120
-10,445
-7,752
141,190
119,197
97,729
81,540
66,101
75,354
59,493
48,433
65,222
56,387
48,246
37,034
25,361
16,524
10,452
3,925
5,150
12,873
11,288
9,923
8,783
8,198
8,850
8,780
8,7808,8508,1988,7839,92311,28812,8735,1503,92510,45216,52425,36137,03448,24656,38765,22248,43359,49375,35466,10181,54097,729119,197141,190-7,752-10,445-8,120-10,020-8,567000
   Common Stock000000000000000000000000-7,752-10,445-8,120-10,020-4000
   Retained Earnings Total Equity00000000-266,1080000000-176,828-163,429-144,201-125,389-105,855-85,627-59,572-32,25400000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
-15,491
-16,017
-4
1
-20
-18
-30
-27
-27
-27
-26
-26
-23
-24
-25
-28
-20
-19
-16
-18
-12
-16
0
0
0
0
0000-16-12-18-16-19-20-28-25-24-23-26-26-27-27-27-30-18-201-4-16,017-15,491000000
   Capital Surplus 
0
0
0
0
0
0
0
0
173,448
178,768
183,376
187,413
191,520
219,582
222,949
225,288
0
0
0
0
0
0
0
270,052
0
0
0
0
0
0
0
0
00000000270,0520000000225,288222,949219,582191,520187,413183,376178,768173,44800000000
   Treasury Stock00000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
5,046
8,265
173,448
178,768
183,376
187,413
191,520
219,582
222,949
225,288
258,258
260,713
263,345
265,112
266,828
268,490
269,626
270,052
275,455
275,614
275,717
275,898
276,082
276,220
276,342
277,701
277,701276,342276,220276,082275,898275,717275,614275,455270,052269,626268,490266,828265,112263,345260,713258,258225,288222,949219,582191,520187,413183,376178,768173,4488,2655,046000000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue2,000
Cost of Revenue-0
Gross Profit2,0002,000
 
Operating Income (+$)
Gross Profit2,000
Operating Expense-5,628
Operating Income-3,628-3,628
 
Operating Expense (+$)
Research Development286
Selling General Administrative5,342
Selling And Marketing Expenses0
Operating Expense5,6285,628
 
Net Interest Income (+$)
Interest Income208
Interest Expense-0
Other Finance Cost-0
Net Interest Income208
 
Pretax Income (+$)
Operating Income-3,628
Net Interest Income208
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-3,057-4,199
EBIT - interestExpense = 0
-3,057
-3,057
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-3,057
Earnings Before Interest and Taxes (EBITDA)-3,628
 
After tax Income (+$)
Income Before Tax-3,057
Tax Provision-0
Net Income From Continuing Ops-3,057-3,057
Net Income-3,057
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses5,628
Total Other Income/Expenses Net571-208
 

Technical Analysis of Cyclerion
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cyclerion. The general trend of Cyclerion is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cyclerion's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Cyclerion Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cyclerion Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 3.79 < 6.25 < 9.4699.

The bearish price targets are: 3.3094 > 2.71 > 2.7.

Know someone who trades $CYCN? Share this with them.πŸ‘‡

Cyclerion Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cyclerion Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cyclerion Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cyclerion Therapeutics Inc. The current macd is 0.0277838.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cyclerion price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Cyclerion. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Cyclerion price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Cyclerion Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartCyclerion Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cyclerion Therapeutics Inc. The current adx is 20.08.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Cyclerion shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Cyclerion Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cyclerion Therapeutics Inc. The current sar is 2.751392.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Cyclerion Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cyclerion Therapeutics Inc. The current rsi is 60.16. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Cyclerion Therapeutics Inc Daily Relative Strength Index (RSI) ChartCyclerion Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cyclerion Therapeutics Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cyclerion price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Cyclerion Therapeutics Inc Daily Stochastic Oscillator ChartCyclerion Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cyclerion Therapeutics Inc. The current cci is 161.33.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Cyclerion Therapeutics Inc Daily Commodity Channel Index (CCI) ChartCyclerion Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cyclerion Therapeutics Inc. The current cmo is 30.94.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Cyclerion Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartCyclerion Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cyclerion Therapeutics Inc. The current willr is -17.72151899.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Cyclerion Therapeutics Inc Daily Williams %R ChartCyclerion Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Cyclerion Therapeutics Inc.

Cyclerion Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cyclerion Therapeutics Inc. The current atr is 0.27894331.

Cyclerion Therapeutics Inc Daily Average True Range (ATR) ChartCyclerion Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cyclerion Therapeutics Inc. The current obv is 291,209,119.

Cyclerion Therapeutics Inc Daily On-Balance Volume (OBV) ChartCyclerion Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cyclerion Therapeutics Inc. The current mfi is 66.38.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Cyclerion Therapeutics Inc Daily Money Flow Index (MFI) ChartCyclerion Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cyclerion Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-26MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-25STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-06-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Cyclerion Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cyclerion Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.165
Ma 20Greater thanMa 503.074
Ma 50Greater thanMa 1003.107
Ma 100Greater thanMa 2002.911
OpenGreater thanClose3.350
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Cyclerion with someone you think should read this too:
  • Are you bullish or bearish on Cyclerion? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cyclerion? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cyclerion Therapeutics Inc

I send you an email if I find something interesting about Cyclerion Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cyclerion Therapeutics Inc.

Receive notifications about Cyclerion Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.